AU-15330
AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity[1].
Product Specifications
CAS Number
[2380274-50-8]
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
PROTACs; SWI/SNF Complex
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/au-15330.html
Purity
99.89
Solubility
DMSO : 140 mg/mL (ultrasonic)
Smiles
O=C(N(C[C@@H]1O)[C@@H](C1)C(N[C@H](C2=CC=C(C(SC=N3)=C3C)C=C2)C)=O)[C@H](C(C)(C)C)NC(CN4CCN(C(C=C(C(C=CC=C5)=C5O)N=N6)=C6N)CC4)=O
Molecular Formula
C39H49N9O5S
Molecular Weight
755.93
Precautions
H302, H315, H319
References & Citations
[1]Xiao L, et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022;601 (7893) :434-439.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
SMARCA2; SMARCA4; von Hippel-Lindau (VHL)
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
